Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

Georgette G Chan, Jay O. Boyle(Memorial Sloan Kettering Cancer Center), Eun Kyung Yang(Cornell University), Fan Zhang(Cornell University), Peter G. Sacks(Memorial Sloan Kettering Cancer Center), Jatin P. Shah(Memorial Sloan Kettering Cancer Center), David R. Edelstein(Manhattan Eye, Ear and Throat Hospital), Robert A. Soslow(Cornell University), Alane Koki(Monsanto (United States)), B. Mark Woerner(Monsanto (United States)), Jaime L. Masferrer(Monsanto (United States)), Andrew J. Dannenberg(Houston Methodist)
PubMed
March 1, 1999
Cited by 715

Abstract

The purpose of this study was to determine whether cyclooxygenase-2 (COX-2) was overexpressed in squamous cell carcinoma of the head and neck (HNSCC). Quantitative reverse transcription-PCR, immunoblotting, and immunohistochemistry were used to assess the expression of COX-2 in head and neck tissue. Mean levels of COX-2 mRNA were increased by nearly 150-fold in HNSCC (n = 24) compared with normal oral mucosa from healthy volunteers (n = 17). Additionally, there was about a 50-fold increase in amounts of COX-2 mRNA in normal-appearing epithelium adjacent to HNSCC (n = 10) compared with normal oral mucosa from healthy volunteers. Immunoblotting demonstrated that COX-2 protein was present in six of six cases of HNSCC but was undetectable in normal oral mucosa from healthy subjects. Immunohistochemical analysis showed that COX-2 was expressed in both HNSCC and adjacent normal-appearing epithelium. Taken together, these results suggest that COX-2 may be a target for the prevention or treatment of HNSCC.


Related Papers

No related papers found

Powered by citation graph analysis